yipf4 Antibody

What is YIPF4 and what cellular functions does it serve?

YIPF4 (YIP1 family member 4) is a 244 amino acid multi-pass membrane protein primarily localized to the Golgi apparatus. It belongs to the YIP1 family of small membrane proteins that interact with Rab GTPases, which are essential regulators of intracellular transport processes. YIPF4 plays crucial roles in membrane trafficking and vesicle biogenesis between the endoplasmic reticulum and Golgi apparatus. The protein contains five putative transmembrane domains and is encoded by a gene located on chromosome 2p22.3, a region associated with several genetic diseases. YIPF4 is also known by alternative names including FinGER4, MGC11061, and Nbla11189 .

The proper functioning of YIPF4 is vital for maintaining cellular homeostasis and facilitating the transport of proteins and lipids within the cell, thereby influencing various cellular functions and signaling pathways. Research has shown YIPF4 expression in primary human keratinocytes and its potential involvement in HPV biology, suggesting tissue-specific functions that may vary with cellular differentiation states .

What types of YIPF4 antibodies are available for research and what are their optimal applications?

Researchers have access to both monoclonal and polyclonal YIPF4 antibodies with distinct characteristics and applications:

The monoclonal YIPF4 antibody (E-7) is an IgG2b kappa light chain antibody that offers high specificity and consistent results across experiments. This antibody is particularly valuable for applications requiring precise epitope recognition and minimal batch-to-batch variation .

The polyclonal YIPF4 antibody generated in rabbits using recombinant human YIPF4 protein (amino acids 1-113) as the immunogen provides broader epitope recognition. This characteristic makes polyclonal antibodies potentially more sensitive for detecting native proteins, especially in applications like immunofluorescence where protein conformation may be preserved .

For optimal application selection:

• Western blotting: Both antibody types perform well for detecting denatured YIPF4

• Immunoprecipitation: Monoclonal antibodies typically provide cleaner results

• Immunofluorescence: Both types are suitable, with polyclonals potentially offering higher sensitivity

• ELISA: Both antibody types demonstrate good performance

How can I optimize YIPF4 antibody use for co-immunoprecipitation studies investigating protein-protein interactions?

Optimizing co-immunoprecipitation (Co-IP) experiments with YIPF4 antibodies requires careful consideration of several parameters based on evidence from successful YIPF4 interaction studies:

• Antibody selection: For YIPF4 Co-IP, both direct antibody capture and epitope-tagged approaches have proven effective. Published research successfully used FLAG-tagged YIPF4 constructs for pulldown experiments, which can provide cleaner results than native protein IP. If using direct YIPF4 antibody precipitation, monoclonal antibodies typically yield more specific interactions with less background .

• Lysis conditions: To preserve YIPF4 interactions, use mild non-ionic detergents:

  • For membrane protein interactions: 1% NP-40 or 1% Triton X-100

  • For weaker interactions: 0.5% CHAPS or digitonin

  • Buffer composition: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA with protease inhibitors

• Cross-linking considerations: For transient interactions, consider using membrane-permeable crosslinkers like DSP (dithiobis[succinimidylpropionate]) at 0.5-2 mM for 30 minutes before lysis.

• Controls: Implement the following critical controls as demonstrated in published YIPF4 interaction studies:

  • GFP-only (or relevant tag-only) negative control

  • FLAG-YIPF4 positive control

  • IgG isotype control

  • Input sample (5-10% of lysate)

• Validation strategy: For novel interactions, confirm using reciprocal Co-IP and at least one orthogonal method (Y2H, proximity ligation, etc.) as demonstrated in the 16E5-YIPF4 interaction studies .

When studying YIPF4 truncation mutants, ensure proper expression validation, as some constructs (e.g., del1–109) may show poor expression. The published successful approach for YIPF4 interaction mapping used a series of truncation mutants expressed with N-terminal epitope tags .

What are the critical parameters for detecting YIPF4 expression changes during cell differentiation using immunofluorescence?

Detecting changes in YIPF4 expression during cell differentiation requires optimization of several parameters based on published studies examining YIPF4 in differentiated keratinocytes and tissue samples:

• Fixation protocol optimization:

  • For cultured cells: 4% paraformaldehyde (10 minutes) followed by permeabilization with 0.1-0.2% Triton X-100

  • For tissue sections: 10% neutral buffered formalin fixation followed by antigen retrieval (citrate buffer pH 6.0)

  • Note: Methanol fixation may alter transmembrane protein epitopes and should be tested carefully

• Antibody dilution and validation:

  • Titrate primary antibodies (typically 1:100-1:500) using positive and negative controls

  • Include differentiation markers as internal controls (e.g., involucrin, keratin markers)

  • Use relevant Golgi markers (e.g., GM130) for colocalization to confirm specificity

• Imaging considerations:

  • Confocal microscopy is preferred over widefield for accurate YIPF4 localization

  • Use z-stack acquisition to fully capture Golgi-localized signals

  • Implement consistent exposure settings across all differentiation stages

• Quantification approach:

  • Mean fluorescence intensity measurements with background subtraction

  • Cell-by-cell analysis rather than field averages

  • Normalization to appropriate housekeeping proteins

Published research has shown that YIPF4 protein levels decrease during primary keratinocyte differentiation, but this reduction is less pronounced in HPV18-positive cells. Interestingly, this pattern was not consistently observed in three-dimensional organotypic raft cultures, highlighting the importance of model system selection and sensitivity of detection methods .

When examining YIPF4 in clinical samples such as cervical intraepithelial neoplastic (CIN) lesions, co-staining with relevant markers (such as 16E4 for HPV infection) provides crucial context for interpretation of expression patterns .

What is known about YIPF4's interaction with HPV proteins and what experimental approaches best characterize this relationship?

YIPF4 has been identified as a binding partner of Human Papillomavirus (HPV) 16E5 protein, with significant implications for understanding HPV biology. The interaction was initially discovered through a yeast two-hybrid (Y2H) screen and subsequently confirmed in cervical cells .

Key aspects of the YIPF4-HPV relationship:

• YIPF4 interacts with the HPV 16E5 oncoprotein, a poorly characterized viral protein

• The interaction appears to be conserved across different E5 proteins, suggesting functional significance

• YIPF4 is expressed in HPV-related clinical samples, including cervical intraepithelial neoplastic lesions

• HPV infection appears to modulate YIPF4 expression during keratinocyte differentiation

Optimal experimental approaches for characterizing this interaction:

• Mapping interaction domains:

  • Truncation mutant analysis revealed that:

    • For 16E5: The first 54 amino acids are sufficient for YIPF4 binding

    • For YIPF4: The N-terminal 138 amino acids play a critical role in the interaction

  • Point mutations rather than just truncations should be used for fine mapping

• Functional analysis of the interaction:

  • siRNA-mediated depletion of YIPF4 (achieving ~80% knockdown)

  • Examination of HPV early protein expression (E6, E7)

  • Assessment of E5-mediated cellular functions (EGFR trafficking, HLA class I presentation)

  • Analysis of cell cycle proteins regulated by E5 (cyclin A, cyclin B)

• Differentiation model systems:

  • Calcium-induced differentiation of keratinocytes

  • Three-dimensional organotypic raft cultures

  • Analysis of clinical samples with appropriate HPV markers

Interestingly, despite confirming the YIPF4-16E5 interaction, research has not yet demonstrated clear functional consequences of YIPF4 depletion on known E5-mediated processes like EGFR trafficking or HLA class I presentation. This suggests YIPF4 may be involved in currently uncharacterized aspects of E5 biology, presenting opportunities for further research .

How does YIPF4 expression change in HPV-positive tissues and what are the best methodological approaches for studying these alterations?

YIPF4 expression patterns in HPV-positive tissues demonstrate interesting dynamics that provide insight into potential virus-host interactions. Research has revealed several key observations and methodological considerations:

Expression patterns in HPV contexts:

• YIPF4 protein levels typically decrease during normal keratinocyte differentiation

• HPV18 positive cells show attenuated reduction of YIPF4 during differentiation

• YIPF4 is detected throughout epithelial layers in organotypic raft cultures of both HPV18-positive and HPV-negative cell lines

• YIPF4 is expressed in clinical samples of HPV16-positive cervical intraepithelial neoplastic (CIN) lesions

Recommended methodological approaches:

• Model system selection:

  Model System	Advantages	Limitations	Key Controls
  Calcium-differentiated keratinocytes	Simple, controlled differentiation	2D system, lacks tissue architecture	Undifferentiated controls, differentiation markers
  Organotypic raft cultures	3D structure, mimics stratified epithelium	Technical complexity, variability	HPV-negative equivalents, differentiation markers
  Clinical samples	Direct disease relevance	Heterogeneity, limited controls	Adjacent normal tissue, HPV markers

• Detection methods optimization:

  • Immunohistochemistry: Use antigen retrieval (citrate buffer, pH 6.0) for formalin-fixed samples

  • Immunofluorescence: Co-staining with HPV markers (e.g., 16E4) and differentiation markers

  • Western blotting: Careful normalization to account for differentiation effects

• Analysis approach:

  • For calcium differentiation: Time course analysis (0, 24, 48, 72 hours)

  • For raft cultures: Layer-by-layer quantification from basal to cornified layers

  • For clinical samples: Grade-specific analysis (e.g., CIN1 vs. CIN3)

• HPV specificity testing:

  • Compare multiple HPV types (HPV16, HPV18, etc.)

  • Use genomes with specific gene knockouts (e.g., HPV18 ΔE5)

Interestingly, research has shown that while YIPF4 levels are maintained in HPV18-positive cells during differentiation, this effect persists even in cells expressing an HPV18 genome lacking E5 expression. This suggests that HPV's effect on YIPF4 is likely mediated by viral proteins other than E5, potentially through E2 based on bioinformatic analysis of the YIPF4 promoter .

What are the most effective controls and troubleshooting strategies when working with YIPF4 antibodies in western blotting applications?

When performing western blotting with YIPF4 antibodies, implementing rigorous controls and troubleshooting strategies is essential for reliable results:

Essential controls:

• Positive controls:

  • FLAG-tagged YIPF4 overexpression lysate

  • Cell lines with known YIPF4 expression (e.g., HEK293T, HeLa)

  • Recombinant YIPF4 protein (particularly the 1-113AA region)

• Negative controls:

  • YIPF4 siRNA-treated samples (achieving ≥80% knockdown)

  • Cell lines with minimal YIPF4 expression

  • Secondary antibody-only controls

• Loading controls:

  • Standard housekeeping proteins (GAPDH, β-actin)

  • For membrane/Golgi proteins, organelle-specific markers (e.g., GM130)

Optimization strategies:

Troubleshooting common issues:

• No or weak signal:

  • Verify protein expression using alternative antibodies or tagged constructs

  • Test different epitope regions (N-terminal vs. C-terminal antibodies)

  • Optimize extraction conditions (detergent type and concentration)

  • Confirm antibody viability with dot blot of recombinant protein

• Multiple bands/non-specific signals:

  • Validate with siRNA knockdown to identify specific band (~27 kDa)

  • Increase washing stringency (0.1% to 0.3% Tween-20)

  • Titrate primary antibody concentration

  • Use monoclonal antibody for higher specificity

• Inconsistent results across experiments:

  • Standardize lysate preparation (fresh vs. frozen)

  • Maintain consistent exposure times for quantitative comparisons

  • Prepare fresh working solutions of antibodies for each experiment

Published research successfully detected YIPF4 protein (~27 kDa) from both endogenous expression and epitope-tagged constructs, with visible differences following siRNA knockdown (showing approximately 50-80% reduction by densitometry) .

What experimental design considerations are critical when studying YIPF4's role in membrane trafficking using immunofluorescence?

Studying YIPF4's role in membrane trafficking requires careful experimental design to properly visualize, quantify, and interpret its dynamics and interactions. Based on YIPF4's known Golgi localization and role in ER-Golgi trafficking, the following considerations are critical:

Experimental design framework:

• Co-localization strategy:

  • Pair YIPF4 antibodies with established markers:

    • Golgi markers: GM130 (cis-Golgi), TGN46 (trans-Golgi)

    • ER markers: Calnexin, PDI

    • Trafficking markers: ERGIC-53, Rab proteins (particularly Rab GTPases)

  • Use different fluorophores with minimal spectral overlap

  • Acquire images at sufficient resolution for organelle discrimination

• Dynamic trafficking studies:

  • Implement cargo trafficking assays:

    • VSVG-GFP temperature-shift assay (40°C to 32°C)

    • Synchronized protein export using reversible ER-exit blocks

  • Consider live-cell imaging with tagged YIPF4 constructs

  • Use photobleaching techniques (FRAP) to measure mobility

• Perturbation approaches:

  • siRNA-mediated YIPF4 depletion (achieving ≥80% knockdown)

  • Overexpression of wild-type and mutant YIPF4

  • Treatment with trafficking inhibitors (BFA, monensin)

  • Consider YIPF4 truncation mutants based on transmembrane domain structure

• Quantification methods:

  • Pearson's correlation coefficient for co-localization

  • Cargo transport rates measured by time-lapse imaging

  • Organelle morphology analysis (size, number, distribution)

  • Intensity-based FRET for protein-protein interactions

Critical controls and validations:

• Antibody validation:

  • Verify specificity using siRNA knockdown in immunofluorescence

  • Compare staining patterns between different antibodies (monoclonal vs. polyclonal)

  • Confirm localization with epitope-tagged constructs

• Expression level considerations:

  • Use inducible expression systems to avoid overexpression artifacts

  • Quantify expression levels relative to endogenous protein

  • Compare multiple cell types (with varying endogenous YIPF4 levels)

• Functional validation:

  • Complement YIPF4 knockdown with siRNA-resistant constructs

  • Pair morphological observations with functional transport assays

  • Consider the impact of cell cycle and differentiation status

Research has established YIPF4 as a Golgi-apparatus localized protein with potential roles in ER to GA trafficking. Its interaction with the HPV 16E5 protein and potential associations with Rab GTPases suggest it may influence multiple trafficking pathways. While YIPF4 depletion did not significantly affect EGFR trafficking in published studies, this negative result underscores the importance of examining multiple cargo types and trafficking routes to fully characterize YIPF4's specific functions .

What are the emerging research directions for YIPF4 and what methodological approaches will be most valuable for these investigations?

The current understanding of YIPF4 points to several promising research directions that warrant further investigation with specialized methodological approaches:

• YIPF4's role in viral pathogenesis:

  • Beyond HPV, examine YIPF4 interactions with other viral proteins that manipulate membrane trafficking

  • Implement CRISPR/Cas9 genome editing of YIPF4 in relevant cell models

  • Develop animal models with tissue-specific YIPF4 knockout/knockdown

  • Apply proteomics to identify the complete YIPF4 interactome during viral infection

• YIPF4 in specialized secretory cell types:

  • Investigate YIPF4 function in professional secretory cells (e.g., pancreatic β-cells, plasma cells)

  • Utilize high-content screening to identify cargo specifically dependent on YIPF4

  • Apply super-resolution microscopy to precisely localize YIPF4 within Golgi subcompartments

  • Develop cargo-specific trafficking assays with quantitative readouts

• YIPF4 in disease contexts beyond viral infection:

  • Examine YIPF4 expression in cancer progression and metastasis

  • Investigate potential roles in neurodegenerative diseases involving secretory pathway dysfunction

  • Explore YIPF4 genetic variants in genome-wide association studies

  • Analyze YIPF4 expression in tissue microarrays across multiple pathologies

• Mechanistic studies of YIPF4 membrane trafficking functions:

  • Characterize YIPF4-Rab GTPase interactions using in vitro binding assays

  • Implement proximity labeling approaches (BioID, APEX) to identify neighboring proteins

  • Apply cryo-electron microscopy to visualize YIPF4-containing complexes

  • Develop in vitro vesicle budding and fusion assays with recombinant YIPF4

The interaction between YIPF4 and HPV E5 proteins represents a particularly intriguing area for further investigation. While this interaction has been confirmed, its functional significance remains unclear as YIPF4 depletion did not affect known E5-mediated processes like EGFR trafficking or HLA class I presentation. This suggests YIPF4 may participate in currently uncharacterized aspects of viral biology .